Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder
- 466 Downloads
To present up-to-date information and recommendations on the management of body weight changes during the use of antiepileptic mood stabilizers in bipolar disorder to help clinicians and patients make well-informed, practical decisions.
Umbrella review. Systematic reviews and meta-analyses on the prevention, treatment, and monitoring of body weight changes as a side effect of the mood stabilizers valproate, lamotrigine, topiramate, and carbamazepine were identified in Embase (2010–2015, no language restrictions).
The search yielded 18 relevant publications on antiepileptic mood stabilizers and weight changes in bipolar disorder.
Relevant scientific evidence was abstracted and put into a clinical perspective by a multidisciplinary expert panel of clinicians with expertise in the treatment of bipolar disorders across all age groups and a patient representative.
Valproate has been proven to be associated with weight gain in up to 50% of its users, and can be detected 2–3 months after initiation. Carbamazepine has been proven to have a low risk of weight gain. Lamotrigine and topiramate are associated with weight loss. Other option for this sentence = Weigth gain has been proven to be associated with valproate use in up to 50% of its users, and can be detected within 2-3 months after initiation.
Each antiepileptic mood stabilizer has specific effects on body weight and accordingly requires a discrete education, prevention, monitoring, and treatment strategy. Clinicians are recommended to adopt an active, anticipatory approach, educating patients about weight change as an important side effect in order to come to informed shared decisions about the most suitable mood stabilizer.
KeywordsBipolar disorder Weight gain Weight loss Anti-obesity agents Body weight changes Valproate Lamotrigine Topiramate Carbamazepine
This study was funded by the Dutch network for quality development in mental health (Netwerk Kwaliteitsontwikkeling GGZ).
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord 2013;15: 1–44Google Scholar
- 5.Zuo S, Fries BE, Szafara K, Regal R (2015) Valproic acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none? PT 40(2):126–132Google Scholar
- 6.Vancampfort D, Stubbs B, Mitchell AJ, De Hert M, Wampers M, Ward PB, Rosenbaum S, Correll CU (2015) Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry 14(3):339–347CrossRefGoogle Scholar
- 7.National Collaborating Centre for Mental health bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care; Updated edition 2014 National Institute for Health and Care Excellence (NICE)Google Scholar
- 10.White W, Elmore L, Luthin DR, Cates ME (2013) Psychotropic-induced weight gain: a review of management strategies. Consultant 53(3):153–160Google Scholar
- 13.Domecq JP, Prutsky G, Leppin A, Sonbol MB, Altayar O, Undavalli C, Wang Z, Elraiyah T, Brito JP, Mauck KF, Lababidi MH, Prokop LJ, Asi N, Wei J, Fidahussein S, Montori VM, Murad MH (2015) Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab 100(2):363–370CrossRefGoogle Scholar
- 25.McIntyre RS, Alsuwaidan M, Goldstein BI, Taylor VH, Schaffer A, Beaulieu S, Kemp DE, Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force (2012) The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid metabolic disorders. Ann Clin Psychiatry 24(1):69–81PubMedGoogle Scholar